CSF2, colony stimulating factor 2, 1437

N. diseases: 1028; N. variants: 7
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.350 Therapeutic group CTD_human Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. 11325840 2001
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.350 Biomarker group BEFREE Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. 12748184 2003
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.350 Biomarker group BEFREE First, immunotherapy with an allogeneic, HER2-positive, GM-CSF-secreting breast tumor vaccine alone or with CY and DOX is safe and induces HER2-specific immunity in patients with metastatic breast cancer. 19805669 2009
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.350 Biomarker group BEFREE Immunization with two recombinant Bacillus Calmette-Guérin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice. 20127358 2010
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.350 Biomarker group BEFREE Thus, we explored the potential immune-modulating effects of sorafenib in a murine HER-2-(neu) overexpressing breast tumor model alone and in combination with a HER-2 targeted granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting vaccine (3T3neuGM). 28282575 2017
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.350 Biomarker group BEFREE We have previously reported that, in a phase I pilot study (ClinicalTrials.gov NCT00095862), a subject with stage IV breast cancer experienced substantial regression of breast, lung, and brain lesions following inoculation with clinical formulations of SV-BR-1-GM, a GM-CSF-secreting breast tumor cell line. 29867922 2018